BAY 43-9006 data at the 16th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics"

September 28 - October 1, 2004

Press Release

Bayer and Onyx Announce Phase II Results of Treatment with BAY 43-9006 In Patients with Advanced Primary Liver Cancer 52 Percent of Patients Experienced Disease Stabilization or Tumor Shrinkage	PDF / 164 KB collect EORTC_20040929-IR-0583_e.pdf
Hepatocellular Carcinoma Fact Sheet	PDF / 205 KB collect Hepatocellular_Carcinoma_FactSheet.pdf HCC Fact Sheet
BAY 43-9006 Clinical Development Portfolio	PDF / 105 KB collect Clinical_Development_Portfolio.pdf BAY 43-9006 Clinical Development Portfolio

Other useful Links

Clinical trials information: www.clinicaltrials.gov

American Cancer Society: www.cancer.org

World Health Organization: www.who.int

National Cancer Institute: www.cancer.gov

You are leaving the Bayer AG website.

Bayer AG is not responsible for the information on the website to which you are linking.

share this page

print site